Akston Biosciences Stock
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics.
Sign up today and learn more about Akston Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Akston Biosciences Stock
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. It was founded in 2011 and headquartered in Beverly, Massachusetts.
Funding History
| February 2013 | $700K |
|---|---|
| May 2015 | $1.6M |
| September 2015 | $250K |
| August 2016 | $3.4M |
| February 2017 | $998K |
| February 2018 | $999K |
| May 2018 | $3.9M |
| June 2019 | $979K |
| April 2020 | $7.8M |
| May 2020 | $924K |
| June 2021 | $19.9M |
| April 2022 | $5.2M |
Management
Co-founder, President, and CEO
Todd C. Zion
Press
businesswire - Aug, 17 2023
Akston Biosciences to Focus on Strong Animal Health Pipelinebiospace - Jan, 23 2023
Akston Biosciences Strengthens Board with Addition of John T. PrestonEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
